| Type 2 Diabetes Mellitus |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.86 |
| Heart |
0 |
0.72 |
| Heart Failure (HF) |
0 |
0.68 |
| Coronary Artery Disease (CAD) |
0 |
0.62 |
| Blindness |
0 |
0.4 |
| Blood |
0 |
0.24 |
| Patient Safety |
0 |
0.99 |
| Renal Disease |
0 |
0.17 |
| Adverse Effects |
0 |
0.16 |
| Clinical Guidelines |
0 |
0.16 |
| Exercise |
0 |
0.16 |
| Health Education and Counseling |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Kidney |
0 |
0.16 |
| Shared Decision-Making |
0 |
0.16 |
| Foot Problems |
0 |
0.11 |
| Cardiovascular disease |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Colorado |
0 |
0.08 |
| Diet |
0 |
0.08 |
| DPP-4 Inhibitors |
0 |
0.08 |
| Endocrinology |
0 |
0.08 |
| Georgia |
0 |
0.08 |
| Hypoglycemia |
0 |
0.08 |
| Maryland |
0 |
0.08 |
| Minnesota |
0 |
0.08 |
| Nutrition |
0 |
0.08 |
| Pedal |
0 |
0.08 |
| Prediabetes |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| SGLT2 Inhibitor |
0 |
0.08 |
| Sulfonylureas |
0 |
0.08 |
| Abdominal Infection |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.07 |
| Diabetic Foot |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Pancreatitis |
0 |
0.07 |
| Weight Management |
0 |
0.07 |